According to Inhibrx's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 903.089. At the end of 2023 the company had a P/S ratio of 998.
Year | P/S ratio | Change |
---|---|---|
2023 | 998 | 102.63% |
2022 | 493 | 111.8% |
2021 | 233 | 139.63% |
2020 | 97.1 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |